stockportfolio.pro
Stocks / DGX vs WST
DGX vs WST
Quest Diagnostics Incorporated and West Pharmaceutical Services, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Quest Diagnostics Incorporated (DGX) | West Pharmaceutical Services, Inc. (WST) | |
|---|---|---|
| Market cap | $22.4B | $23.4B |
| Revenue (latest FY) | $11.04B | $3.07B |
| Net income (latest FY) | $992.00M | $493.70M |
| Revenue growth (5y CAGR) | 3.2% | 7.4% |
| Net margin | 9.0% | 16.1% |
| Return on equity | 13.8% | 15.5% |
| P/E ratio | 22.3 | 44.4 |
| Dividend yield | 1.7% | 0.3% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DGX — free Open WST — freeFrequently asked questions
Which is bigger, DGX or WST?
West Pharmaceutical Services, Inc. is larger by market capitalization — $23.4B versus $22.4B.
Which grows faster, DGX or WST?
Over the last five fiscal years, West Pharmaceutical Services, Inc. grew revenue faster — 7.4%/yr versus 3.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.